Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Exelixis
Incyte Corporation
St. Joseph's Hospital and Medical Center, Phoenix
Wake Forest University Health Sciences
Alaunos Therapeutics
National Institutes of Health Clinical Center (CC)
Jazz Pharmaceuticals
University of Oklahoma
Children's Hospital Medical Center, Cincinnati
Regeneron Pharmaceuticals
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, San Francisco
Mayo Clinic
Duke University
Bristol-Myers Squibb
Karyopharm Therapeutics Inc
Indiana University
Weill Medical College of Cornell University
University of Florida
Boston Scientific Corporation
M.D. Anderson Cancer Center
RTOG Foundation, Inc.
Case Comprehensive Cancer Center
Children's Hospital Medical Center, Cincinnati
Massachusetts General Hospital
Stanford University
Pfizer
University of Alabama at Birmingham
Medical College of Wisconsin
Duke University
Medical University of South Carolina
M.D. Anderson Cancer Center
University of Louisville
Burzynski Research Institute
Beth Israel Medical Center
H. Lee Moffitt Cancer Center and Research Institute
NYU Langone Health
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Isarna Therapeutics GmbH
London Health Sciences Centre
H. Lee Moffitt Cancer Center and Research Institute
Duke University
Case Comprehensive Cancer Center
Duke University
National Institutes of Health Clinical Center (CC)
Novartis